AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.
Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Use these Linux commands to quickly search and find anything from the Linux terminal, without digging through folders in a GUI file manager.
Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...
This study offers a valuable advance for neuroscience by extending a visualization tool that enables intuitive assessment of how dendritic and synaptic currents shape the output of neurons. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback